A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples